Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer
Yochum Z, Cades J, Wang H, Chatterjee S, Simons B, O’Brien J, Khetarpal S, Lemtiri-Chlieh G, Myers K, Huang E, Rudin C, Tran P, Burns T. Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer. Oncogene 2018, 38: 656-670. PMID: 30171258, PMCID: PMC6358506, DOI: 10.1038/s41388-018-0482-y.Peer-Reviewed Original ResearchMeSH KeywordsAcrylamidesAmino Acid SubstitutionAniline CompoundsCarcinoma, Non-Small-Cell LungCell Line, TumorDrug Resistance, NeoplasmEpithelial-Mesenchymal TransitionErbB ReceptorsHEK293 CellsHumansLung NeoplasmsMutation, MissenseNeoplasm ProteinsNuclear ProteinsPiperazinesProtein Kinase InhibitorsTwist-Related Protein 1ConceptsEGFR tyrosine kinase inhibitorsTyrosine kinase inhibitorsEGFR-TKI resistanceGeneration EGFR tyrosine kinase inhibitorsCell lung cancerEGFR-mutant NSCLCLung cancerTKI resistanceTwist1 overexpressionFirst-generation EGFR tyrosine kinase inhibitorsThird-generation EGFR tyrosine kinase inhibitorEGFR-mutant lung cancerEGFR-mutant NSCLC cellsFirst-line settingLong-term efficacyDe novo resistanceT790M mutationErlotinib-induced apoptosisEpithelial-mesenchymal transition transcription factorsDrivers of EMTDrivers of resistanceEMT transcription factor TWIST1Osimertinib resistanceErlotinib resistanceNovo resistanceParadoxical functions of ZEB1 in EGFR -mutant lung cancer: tumor suppressor and driver of therapeutic resistance
Yochum Z, Socinski M, Burns T. Paradoxical functions of ZEB1 in EGFR -mutant lung cancer: tumor suppressor and driver of therapeutic resistance. Journal Of Thoracic Disease 2016, 8: e1528-e1531. PMID: 28066651, PMCID: PMC5179406, DOI: 10.21037/jtd.2016.11.59.Peer-Reviewed Original ResearchNon-small cell lung cancerLung cancerEGFR-mutant lung cancerCell lung cancerCancer-related deathAmplification/mutationEGFR mutationsALK translocationKRAS mutationsDistinct subtypesTherapeutic resistanceCancerMolecular driversPatientsTumor suppressorParadoxical functionsMutationsSubtypesSignificant advancesZEB1